急诊科单次静脉注射常规胰岛素与赖脯胰岛素治疗高钾血症的比较:SIR-LISPRO 试验
这项回顾性队列研究纳入两家学术中心急诊科于2022年1月1日至2023年1月1日期间接受5单位静脉胰岛素治疗高钾血症的成人患者,比较静脉常规胰岛素与赖脯胰岛素的安全性和有效性。主要结局为胰岛素后6小时内血清钾变化,主要安全结局为6小时内低血糖事件(血糖<70 mg/dl)或需补充葡萄糖的比例。共237例患者纳入,129例接受常规胰岛素,108例接受赖脯胰岛素。赖脯胰岛素组降钾幅度更大(uMD:-0.24;95%CI:-0.42,-0.06),但低血糖风险更高(16% vs 7%;uOR:2.49;95%CI:1.08,6.09)。作者认为需进一步前瞻性对照研究评估两种胰岛素制剂差异的临床意义。
要点
- 在急诊高钾血症成人中,静脉赖脯胰岛素较常规胰岛素降钾幅度更大(uMD:-0.24;95%CI:-0.42,-0.06)。
- 赖脯胰岛素组低血糖发生率16%,常规胰岛素组7%,赖脯胰岛素低血糖风险更高(uOR:2.49;95%CI:1.08,6.09)。
- 研究纳入237例接受5单位静脉胰岛素治疗的患者,其中129例用常规胰岛素,108例用赖脯胰岛素。
- 主要安全结局为胰岛素后6小时内低血糖事件(血糖<70 mg/dl)或需补充葡萄糖。
- 作者认为需进一步前瞻性对照研究评估两种胰岛素制剂差异的临床意义。
适用人群与场景
- 两家学术中心急诊科收治的成人高钾血症患者,接受5单位静脉胰岛素治疗。
- 研究期间为2022年1月1日至2023年1月1日。
处置流程与药物剂量
- 高钾血症患者接受5单位静脉胰岛素治疗,研究比较常规胰岛素与赖脯胰岛素。
- 主要结局为胰岛素后6小时内血清钾变化;主要安全结局为6小时内低血糖事件(血糖<70 mg/dl)或需补充葡萄糖。
研究设计与关键结果
- 回顾性队列研究,纳入两家学术中心237例急诊高钾血症成人,129例接受静脉常规胰岛素,108例接受静脉赖脯胰岛素。
- 赖脯胰岛素组较常规胰岛素组降钾幅度更大(uMD:-0.24;95%CI:-0.42,-0.06)。
- 赖脯胰岛素组低血糖发生率16%,常规胰岛素组7%,赖脯胰岛素低血糖风险更高(uOR:2.49;95%CI:1.08,6.09)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为需进一步前瞻性对照研究评估两种胰岛素制剂差异的临床意义。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Hyperkalemia is a potentially life-threatening electrolyte disturbance that is present in 2 % to 3 % of emergency department (ED) patient admissions. These patients are commonly treated with intravenous (IV) insulin. Standard of care consists of administering IV insulin regular, but other insulin formulations might be safer and/or more effective, however this has yet to be explored.
OBJECTIVE: To evaluate the safety and effectiveness of insulin lispro and insulin regular administered intravenously for the treatment of hyperkalemia in ED patients.
METHODS: This was a retrospective cohort study that investigated adults that were admitted to the ED of two academic centers and treated for hyperkalemia with 5 units of IV insulin therapy from January 1, 2022, through January 1, 2023. The primary outcome was the change in serum potassium within 6 h following IV insulin regular compared to IV insulin lispro. The primary safety outcome was the proportion of patients who had a hypoglycemic event (blood glucose <70 mg/dl) or required supplemental dextrose administration within 6 h post-insulin administration. Demographic, clinical characteristics, clinical management, and the outcome of change in potassium were associated using linear regression. Dichotomous outcomes pertaining to hypoglycemia were estimated using logistic regression.
RESULTS: Among the 237 patients who met inclusion criteria, 129 received insulin regular, and 108 patients received insulin lispro. We observed a larger decrease in potassium in those that received insulin lispro compared to those that received insulin regular (uMD: -0.24; 95 %CI: -0.42, -0.06). The odds of hypoglycemia were greater among those who received insulin lispro (16 %) compared to insulin regular (7 %) (uOR: 2.49; 95 %CI: 1.08, 6.09).
CONCLUSIONS: Intravenous insulin lispro resulted in a statistically significant reduction of serum potassium but resulted in a higher likelihood of hypoglycemia compared to IV insulin regular. Further prospective, controlled studies are needed to assess the clinical significance of the differences between insulin formulations.
参考来源
- Kroll C, Khan M, Sun J, et al. Comparison of Single-Dose Intravenous Insulin Regular vs. Insulin Lispro for Hyperkalemia Treatment in the Emergency Department: The SIR-LISPRO Trial. Am J Emerg Med. 2025. PMID: 41477935. doi:10.1016/j.ajem.2025.12.031
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。